Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.61 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariporide SCHEMBL6261845 | 0.99 | SLC9A1 (0.63) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL221094 | 0.99 | SLC9A1 (0.63) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL1229789 | 0.99 | SLC9A1 (0.60) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL220085 | 0.99 | SLC9A1 (0.60) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Hydrochloric Acid SCHEMBL8816752 | 0.88 | SLC9A1 (0.47) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| SCHEMBL8743805 | 0.87 | SLC9A1 (0.47) | SLC9A1SLC9A2PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL8743814 | 0.86 | SLC9A1 (0.46) | SLC9A1SLC9A2PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL8983516 | 0.86 | SLC9A1 (0.46) | SLC9A1SLC9A2PLAUCA1CA2 | |
| SCHEMBL8647598 | 0.85 | SLC9A1 (0.44) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL936191 | 0.84 | ALDH1A1 (0.48) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053134-A1 | PERFUSION SOLUTION | ORGAN TRANSP PTY LTD (AU) | 2026-02-26 | — | — | US | claimed |
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250049747-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | TRUSTEES OF TUFTS COLLEGE | 2025-02-13 | — | — | US | claimed |
| EP-4447955-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | Trustees of Tufts College (US) | 2024-10-23 | — | — | EP | claimed |
| US-20240334925-A9 | PERFUSION SOLUTION | PERFUSION FLUID TECHNOLOGIES INC (US) | 2024-10-10 | — | — | US | claimed |
| US-12082575-B2 | Perfusion solution | Organ Transport Pty Ltd (AU) | 2024-09-10 | — | — | US | claimed |
| US-20240090494-A1 | PERFUSION SOLUTION | ORGAN TRANSP PTY LTD (AU) | 2024-03-21 | — | — | US | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| US-20240041804-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | FONDATION ESPERARE (CH) | 2024-02-08 | — | — | US | claimed |
| WO-2001045716-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PHYSIOLOGICALLY ACCEPTABLE VANADIUM COMPOUND, SALT OR COMPLEX AND A NA+/H+ EXCHANGE INHIBITOR | GHO'ST HOLDING B.V. (NL) | 2001-06-28 | — | — | WO | claimed |
| WO-2000067756-A1 | METHODS FOR CONTROLLING INTRAOCULAR PRESSURE | THE TRUSTEES OF THE UNIVERSTIY OF PENNSYLVANIA (US) | 2000-11-16 | — | — | WO | claimed |
| WO-2000038661-A2 | THE UTILISATION OF INHIBITORS OF THE SODIUM HYDROGEN EXCHANGER FOR PRODUCING A MEDICAMENT FOR PREVENTING ORGAN DYSFUNCTIONS AND DISEASES RELATED TO A PARTICULAR AGE AND FOR PROLONGING LIFE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0950418-A2 | Composition for preventing or treating ischemic disease | Takeda Chemical Industries, Ltd. (JP) | 1999-10-20 | — | — | EP | claimed |
| EP-0937464-A2 | Combined pharmaceutical preparation containing inhibitors of the sodium hydrogen exchange and a medicament for the treatment of cardiovascular diseases | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-08-25 | — | — | EP | claimed |
| EP-0916337-A2 | Use of inhibitors of the sodium-hydrogen exchange in the manufacture of amedicament for reducing unwanted effects of compounds on the heart. | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-19 | — | — | EP | claimed |
| EP-0909559-A2 | Use of inhibitors of the sodium hydrogen exchange in the manufacture of a medicament for treatment or prophylaxis of diseases of the central nervous system | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-21 | — | — | EP | claimed |
| CN-1212149-A | Use of inhibitor of Na+/H+ exchanger for production of medicament | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-03-31 | — | — | CN | claimed |
| CN-1209995-A | Use of sodium-hydrogen exchanger inhibitors for the production of a medicament for reducing the adverse effects of substances on the heart | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-03-10 | — | — | CN | claimed |
| CN-1209316-A | Combined medicinal preparation of sodium/hydrogen exchange-pump inhibitor and medicine for treatment of angiocardiopathy | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-03-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041804-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | NHERF1, SLC9A1, SLC9A2 | SLC9A1 2/4885SLC9A2 3/4885CNR2 1955/4885 |
| US-20250049747-A1 | USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCERS INCLUDING GLIOBLASTOMA | MTOR, KCNN1, HCN4 | SLC9A1 25/4885SLC9A2 27/4885CNR2 1274/4885 |
| US-20260053134-A1 | PERFUSION SOLUTION | ATP2A1, SLC8B1, GLS | SLC9A1 63/4885SLC9A2 155/4885CNR2 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.